Amended and Restated Change of Control Retention and Severance AgreementRetention and Severance Agreement • August 9th, 2004 • Cepheid • Laboratory analytical instruments • California
This Amended and Restated Change of Control Retention and Severance Agreement (the “Agreement”) is made and entered into as of May 18, 2004 (the “Effective Date”), by and between Cepheid and John Sluis (the “Executive”) and amends and restates in its entirety any Change of Control Retention and Severance Agreement by and between Cepheid and Executive existing prior to the date hereof. Capitalized terms used in this Agreement shall have the meanings set forth in Section 3 below.
REAL-TIME INSTRUMENT PATENT LICENSE AGREEMENTPatent License Agreement • August 9th, 2004 • Cepheid • Laboratory analytical instruments • California
This Agreement, effective April 5, 2004 (the “Effective Date”), is made by and between Applera Corporation, a corporation of the State of Delaware, through its Applied Biosystems Group, having an office at 850 Lincoln Centre Drive, Foster City, California 94404 and Celera Diagnostics, LLC, an indirectly wholly owned subsidiary of the Applera Corporation (“Applera”), and Cepheid, a corporation of the State of California having an office at 904 Caribbean Drive, Sunnyvale, California 94089 (“Licensee”) (each of Applera and Licensee, a “Party” and, collectively, the “Parties”).
April 23, 2004 Juan Herrero Vice President of Life Science & Drug Discovery Fisher ScientificCepheid • August 9th, 2004 • Laboratory analytical instruments
The symbol [***] is used to indicate that a portion of the exhibit has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portion.Ivd Products Patent License Agreement • August 9th, 2004 • Cepheid • Laboratory analytical instruments
This LICENSE AGREEMENT (the “Agreement”) is entered into effective as of the this July 1, 2004, by and between Cepheid, a California corporation with its principal place of business at 904 Caribbean Drive, Sunnyvale, California 94089-1189 (“CEPHEID”) and F. Hoffmann-La Roche Ltd, a Swiss limited liability company with its principal place of business at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche/Basel”), on behalf of itself and Roche Molecular Systems, Inc., a Delaware corporation with its principal place of business at 4300 Hacienda Drive, Pleasanton, California 94588 USA (“Roche/USA”) (Roche/Basel and Roche/USA shall hereinafter be referred to collectively (or separately as the context requires) as “Roche”) (hereinafter CEPHEID and Roche may separately be referred to as a “Party” or collectively referred to as “the Parties”).
